-
More than two million people living with HIV/AIDS in low and middle income countries now have access to antiretroviral therapy (ART), according to a recent report.
-
The debate surrounding the relative merits of abstinence and fidelity vs. condom use (as if the two were mutually exclusive) remains a hotly contested issue, at least in the United States, where it has even spilled over into U.S. international family planning policy.
-
Prophylaxis against pcp remains the single most cost-effective intervention in HIV+ patients at risk. But treatment has, in some ways, become a moving target in some patients, as their CD4 count rises and falls with newer HIV therapies, medication side effects, and variable compliance.
-
The Food and Drug Administration (FDA) granted approval, on May 23, 2007, to a generic formulation of zidovudine capsules, 100 mg, manufactured by Cipla Limited, of Mumbai, India.
-
The latest microbicide clinical trials will use antiretroviral therapy (ART), which holds both promise and more challenges for investigators.
-
Microbicide research suffered a setback earlier this year when a phase III clinical trial studying cellulose sulfate to block HIV infection was stopped prematurely because there appeared to be a higher rate of HIV infections among the study group than the control group.
-
FDA recently announced these approvals:
Schwartz Bioscience's Neupro (rotigotine transdermal system), a skin patch designed to treat symptoms of early Parkinson's disease.
-
Studies in the U.S. estimate that adverse drug events account for up to 28% of emergency department visits and 25% of ambulatory care encounters and that up to 70% of these visits are preventable.
-
'Lights camera:' Bill calls for videotaped surgeries; Medical researchers not as unbiased as they think
-
A recent study suggests that emergency medicine patients may not have a high level of acceptance of the practice of providing an exemption to informed consent for research involving emergency medical settings.